Advertisement

Impact of a geriatric intervention conducted in nursing homes on inappropriate prescriptions of antipsychotics

  • Clarisse Laffon de MazièresEmail author
  • Maryse Lapeyre-Mestre
  • Bruno Vellas
  • Philipe de Souto Barreto
  • Yves Rolland
Research Paper

Key Summary Points

Aim

To examine the added value of a geriatrician intervention in a nursing home (NH) engaged in an 18-month quality assurance exercise on the potentially inappropriate prescription of antipsychotics (PIPA), compared to straightforward nursing home audit feedback.

Findings

Our study showed that the intervention, including collaborative work meetings between a geriatrician and NH staff, had no effects on PIPA. However, we found that feedback from each NH quality assurance audit had a substantial impact, reducing PIPA by more than 20% in the two study groups.

Message

The involvement of the NH in a quality assurance approach and the high rate of antipsychotic prescriptions highlighted in a quality assurance audit lead to improvements in the level and quality of antipsychotic prescriptions.

Abstract

Purpose

To study the effect of a quality assurance approach in a nursing home, with or without the intervention of a geriatrician, on the potentially inappropriate prescription of antipsychotics (PIPA) at 18 months; and to identify the factors associated with PIPA after 18 months of intervention (T18).

Methods

We used data from a multicentre individually tailored controlled trial (IQUARE study). The study population comprised residents included in the IQUARE study with at least one potentially inappropriate prescription of antipsychotics at baseline (T0) who were still in nursing home at T18 (n = 636; nursing homes = 175). The control group received individual feedback from the quality assurance audit performed at baseline. The intervention group also had at least 5 collaborative work meetings with a geriatrician over an 18-month period. We used a multilevel logistic regression model.

Results

The rates of inappropriate antipsychotic drug prescribing were 66.5% and 45.2% at T0 and T18, respectively. This decrease in the rate of PIPA is significant (p < 0.001). A significant decrease was found within each group: in the intervention arm (68.1% at T0 vs. 44.6% at T18; p < 0.001) and in the control arm (65.2% at T0 vs. 45.6% at T18; p < 0.001). Multivariate analysis did not highlight any statistically significant association between living in a nursing home having received an intervention and PIPA at T18.

Conclusions

Collaborative work meetings with a geriatrician does not provide significant added value to a global quality assurance approach towards PIPA. Individual feedback to each nursing home appears to have a substantial impact on decreasing PIPA.

Keywords

Nursing homes Inappropriate prescribing Antipsychotics Older persons Intervention 

Notes

Author contributions

CLdM and YR had full access to all of the study data and assume responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: YR. Acquisition of data: YR. Analysis and interpretation of data: All authors. Critical revision of the manuscript for important intellectual content: All authors. Drafting of the manuscript: All authors. Statistical analysis: CLdM, ML-M and PdSB. Final approval of the version to be published: All authors.

Funding

The IQUARE study was funded by a grant from the Regional Health Agency of the Midi-Pyrénées region (Agence Régionale de Santé—Midi-Pyrénées). This work was carried out as part of the doctoral research of Clarisse Laffon de Mazières, who received research fellowship funding (Allocation Jeunes Chercheurs 2012—Toulouse University Hospital).

Compliance with ethical standards

Conflict of interest

The authors have reported no conflict of interest.

Ethical approval

To develop the IQUARE study, we followed the principles of the Declaration of Helsinki and complied with ethical standards in France. The trial protocol was approved by the Toulouse University Hospital Ethics Committee and the Consultative Committee for Treatment of Research Information on Health (CNIL: 07-438).

Informed consent

The consent of each residents was obtained by an information leaflet delivered at each resident included in the study, their family and general practitioner. If the residents or their family or the general practitioner refused to participate, the residents was exclued to the study.

Sponsor’s role

The funder contributed to data collection. The funder had no influence on the analysis and interpretation of data, or on the preparation, review, or approval of the manuscript.

References

  1. 1.
    Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360(3):225–235.  https://doi.org/10.1056/nejmoa0806994 CrossRefGoogle Scholar
  2. 2.
    Schneider LS, Dagerman K, Insel PS (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14(3):191–210.  https://doi.org/10.1097/01.jgp.0000200589.01396.6d CrossRefGoogle Scholar
  3. 3.
    Shin J-Y, Choi N-K, Jung S-Y, Lee J, Kwon JS, Park B-J (2013) Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: a population-based, case-crossover study. J Psychopharmacol Oxf Engl. 27(7):638–644.  https://doi.org/10.1177/0269881113482530 CrossRefGoogle Scholar
  4. 4.
    Maust DT, Kim HM, Seyfried LS et al (2015) Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 72(5):438–445.  https://doi.org/10.1001/jamapsychiatry.2014.3018 CrossRefGoogle Scholar
  5. 5.
    Schneider LS, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294(15):1934–1943.  https://doi.org/10.1001/jama.294.15.1934 CrossRefGoogle Scholar
  6. 6.
    National Institute for Health and Care Excellence (2006) Dementia: supporting people with dementia and their carers in health and social care. Guidance and guidelines. https://www.nice.org.uk/guidance/cg42. Accessed 12 Mar 2018
  7. 7.
    APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS et al (2007) American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Second edition. Am J Psychiatry 164:5–56Google Scholar
  8. 8.
    Reus VI, Fochtmann LJ, Eyler AE et al (2016) The American Psychiatric Association Practice Guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry 173(5):543–546.  https://doi.org/10.1176/appi.ajp.2015.173501 CrossRefGoogle Scholar
  9. 9.
    Alzheimer’s Society (2011) Optimising treatment and care for people with behavioural and psychological symptoms of dementia. http://www.alzheimers.org.uk/site/scripts/download_info.php?downloadID=609. Accessed 12 Mar 2018.
  10. 10.
    Thompson Coon J, Abbott R, Rogers M, Whear R, Pearson S, Lang I et al (2014) Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: a systematic review. J Am Med Dir Assoc 15:706–718.  https://doi.org/10.1016/j.jamda.2014.06.012 CrossRefGoogle Scholar
  11. 11.
    Rovner BW, Edelman BA, Cox MP, Shmuely Y (1992) The impact of antipsychotic drug regulations on psychotropic prescribing practices in nursing homes. Am J Psychiatry 149:1390–1392.  https://doi.org/10.1176/ajp.149.10.1390 CrossRefGoogle Scholar
  12. 12.
    Rochon PA, Stukel TA, Bronskill SE, Gomes T, Sykora K, Wodchis WP et al (2007) Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 167:676–683.  https://doi.org/10.1001/archinte.167.7.676 CrossRefGoogle Scholar
  13. 13.
    Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH (2010) Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med 170:89–95.  https://doi.org/10.1001/archinternmed.2009.469 CrossRefGoogle Scholar
  14. 14.
    Maust DT, Kim HM, Chiang C, Kales HC (2018) Association of the Centers for Medicare & Medicaid Services’ National partnership to improve dementia care with the use of antipsychotics and other psychotropics in long-term care in the United States from 2009 to 2014. JAMA Intern Med 178:640–647.  https://doi.org/10.1001/jamainternmed.2018.0379 CrossRefGoogle Scholar
  15. 15.
    Rolland Y, Mathieu C, Piau C, Cayla F, Bouget C, Vellas B et al (2016) Improving the quality of care of long-stay nursing home residents in France. J Am Geriatr Soc 64:193–199.  https://doi.org/10.1111/jgs.13874 CrossRefGoogle Scholar
  16. 16.
    de Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F et al (2013) A multicentric individually-tailored controlled trial of education and professional support to nursing home staff: research protocol and baseline data of the IQUARE study. J Nutr Health Aging 17:173–178.  https://doi.org/10.1007/s12603-013-0008-9 CrossRefGoogle Scholar
  17. 17.
    de Laffon Mazières C, Lapeyre-Mestre M, Vellas B, de Souto Barreto P, Rolland Y (2015) Organizational factors associated with inappropriate neuroleptic drug prescribing in nursing homes: a multilevel approach. J Am Med Dir Assoc 16:590–597.  https://doi.org/10.1016/j.jamda.2015.01.092 CrossRefGoogle Scholar
  18. 18.
    Laroche M-L, Charmes J-P, Merle L (2007) Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol 63:725–731.  https://doi.org/10.1007/s00228-007-0324-2 CrossRefGoogle Scholar
  19. 19.
    Haute autorité de Santé (2009) Recommandations de bonne pratique. Maladie d’Alzheimer et maladies apparentées : prise en charge des troubles du comportement perturbateurs. https://www.has-sante.fr/portail/upload/docs/application/pdf/2009-07/maladie_dalzheimer-troubles_du_comportement_perturbateurs-recommandations.pdf. Accessed 15 Mar 2018
  20. 20.
    Haute Autorité de Santé (2009) Recommandations de bonne pratique. Confusion aiguë chez la personne âgée: prise en charge initiale de l’agitation. https://www.has-sante.fr/portail/upload/docs/application/pdf/2009-07/confusion_aigue_chez_la_personne_agee_-_recommandations_2009-07-08_16-58-24_661.pdf. Accessed 15 Mar 2018
  21. 21.
    Walsh KA, Dennehy R, Sinnott C et al (2017) Influences on decision-making regarding antipsychotic prescribing in nursing home residents with dementia: a systematic review and synthesis of qualitative evidence. J Am Med Dir Assoc 18(10):897.e1–897.e12.  https://doi.org/10.1016/j.jamda.2017.06.032 CrossRefGoogle Scholar
  22. 22.
    Carnahan RM, Brown GD, Letuchy EM et al (2017) Impact of programs to reduce antipsychotic and anticholinergic use in nursing homes. Alzheimers Dement Transl Res Clin Interv. 3(4):553–561.  https://doi.org/10.1016/j.trci.2017.02.003 CrossRefGoogle Scholar
  23. 23.
    Rolland Y, van Abellan Kan G, Hermabessiere S, Gerard S, Guyonnet Gillette S, Vellas B (2009) Descriptive study of nursing home residents from the REHPA network. J Nutr Health Aging 13:679–683CrossRefGoogle Scholar
  24. 24.
    Larrayadieu A, van Abellan Kan G, Piau A, Soto Martin M, Nourhashemi F, Rolland Y et al (2011) Associated factors with antipsychotic use in assisted living facilities: a cross-sectional study of 4367 residents. Age Ageing 40:368–375.  https://doi.org/10.1093/ageing/afr032 CrossRefGoogle Scholar
  25. 25.
    de Mauleon A, Sourdet S, Renom-Guiteras A, Gillette-Guyonnet S, Leino-Kilpi H, Karlsson S et al (2014) Associated factors with antipsychotic use in long-term institutional care in eight European countries: results from the RightTimePlaceCare study. J Am Med Dir Assoc 15:812–818.  https://doi.org/10.1016/j.jamda.2014.06.015 CrossRefGoogle Scholar

Copyright information

© European Geriatric Medicine Society 2019

Authors and Affiliations

  1. 1.Department of Geriatric MedicineToulouse University Hospital (CHU de Toulouse)ToulouseFrance
  2. 2.Inserm UMR 1027ToulouseFrance
  3. 3.Department of Medical and Clinical PharmacologyCIc 1436, CHU de ToulouseToulouseFrance

Personalised recommendations